On Friday, Shares of bluebird bio Inc (NASDAQ:BLUE), subtract -13.29% and closed at $56.57 in the last trading session. The last trading range of the stock ranges between $56.53 and $63.87. bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, will outline recently key activities underway intended to advance the company’s LentiGlobin programs in transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD). The presentation will focus on three key aspects of these activities: 1) potential improvements in transduction efficiency and manufacturing; 2) updates to the protocol for the company’s ongoing HGB-206 clinical trial in SCD; and 3) regulatory plans for the company’s LentiGlobin drug product candidate in TDT.
“At bluebird bio we have an incredibly ambitious aim: to deliver one-time, transformative therapies to patients with rare genetic diseases and cancer. We are relentless in our efforts to continue innovating in pursuit of that aim, and we have made substantial advances in the transduction and manufacturing processes, translational research, and clinical development,” said Nick Leschly, chief bluebird. “By incorporating manufacturing Process 2 into our LentiGlobin clinical trials, we believe we can achieve our ultimate aim of increasing hemoglobin production in patients treated with LentiGlobin drug product. In sickle cell disease we have used our early clinical data to identify and implement multiple distinct improvements with the potential to overcome the unique challenges presented by this complex disease. We are hopeful that the tremendous work done by our research and development teams will yield improved outcomes for patients in the clinic in 2017 and beyond, and that the regulatory progress we are making will facilitate us to bring these treatments to patients as quickly as possible. We anticipate seeing many catalysts across our programs in the next 15 months, counting initial clinical data from our Phase 1 clinical study of our bb2121 product candidate in relapsed/refractory multiple myeloma and updates on our Lenti-D program in cerebral adrenoleukodystrophy.”
Energy Transfer Equity LP (NYSE:ETE), jumped 0.38% and closed at $15.72 in the last trading session. The last trading range of the stock ranges between $15.46 and $15.89. The company’s Market capitalization is $16.49 Billion with the total outstanding Shares of 1.04 billion. Sunoco LP (SUN) (“Sunoco”) declared recently that one of its wholly owned auxiliaries accomplished the acquisition of the retail convenience store assets and wholesale fuel business from Denny Oil for about $53 million. This acquisition includes six company-operated locations and wholesale fuel supply contracts for a network of about 120 independent dealer-owned and dealer-operated locations and a commercial fuels business in the Eastern Texas and Louisiana markets. The business distributes about 90 million gallons of retail and wholesale fuel annually. This acquisition strengthens, and in some cases establishes, Sunoco’s existing convenience store and wholesale fuel distribution business in East Texas and Louisiana. This transaction was funded using amounts available under Sunoco’s revolving credit facility and is expected to be right away accretive to Sunoco with respect to distributable cash flow.
Take-Two Interactive Software, Inc. (NASDAQ:TTWO), gained 0.80% and closed at $42.69 in the last trading session. The last trading range of the stock ranges between $42.65 and $43.97. The company’s Market capitalization is $3.70 Billion with the total outstanding Shares of 86.02 million. During the 52-week trading session the minimum price at which share price traded, registered at $31.01 and reached to max level of $46.78. 2K recently declared the debut of NHL® SuperCard 2K17, a new collectible card-battling game featuring NHL players. With NHL All-Star Logan Couture gracing the cover, NHL® SuperCard 2K17 is now available for free download from the App Store for iOS devices, counting the iPhone®, iPad® and iPod touch®, in addition to the Google Play Store and Amazon Appstore for Android™ devices.
“From the huge number of current players to quick games to competitive season play, NHL® SuperCard 2K17 is an awesome way to stay virtually connected to all things NHL,” said Logan Couture. “Serving as the cover athlete for NHL® SuperCard 2K17 is a great honor, and I am excited to assist further interest in NHL across sports and gaming fans as I kick off regular season action this week with the defending 2016 Western Conference Champions.”
NHL® SuperCard 2K17 invites players to build teams of NHL players, train their skill sets to full potential and hit the ice to compete in exhibition games, in addition to test their capabilities in season-driven action. The game features more than 400 collectible cards in active play, with each card representing one of seven different rarity levels. Alongside cover athlete Couture, fans will find various current NHL players, counting Nicklas Backstrom, Drew Doughty, Claude Giroux, Ryan Kesler, Carey Price and Tyler Seguin. In addition, players may complement their gameplay experiences by purchasing individual card packs.